A

Avalo Therapeutics
D

AVTX

17.190
USD
-1.01
(-5.52%)
مغلق
حجم التداول
44,623
الربح لكل سهم
-2
العائد الربحي
-
P/E
-4
حجم السوق
921,899,511
المقالات
المزيد

العنوان: Avalo Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.